| Disease Domain | Count |
|---|---|
| Nervous System Diseases | 2 |
| Infectious Diseases | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 2 |
| Peptides | 1 |
Target |
Mechanism COX inhibitors [+1] |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc. United States |
First Approval Date25 Jun 1980 |
Target |
Mechanism SSTR4 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism MIF inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2027 |
Sponsor / Collaborator |
Start Date15 Oct 2026 |
Sponsor / Collaborator |
Start Date10 Jul 2026 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
TT-232(University of Pécs) ( SSTR4 ) | Pain More | Preclinical |
Compound 37 (University of Pecs) ( MIF ) | Shock, Septic More | Preclinical |
Meclofenamate Sodium ( COXs x TRPM4 ) | Seizures More | Preclinical |
AMG7905 ( TRPV1 ) | Analgesia More | Pending |
A-1165901 ( TRPV1 ) | Analgesia More | Pending |





